Wellington Management Group LLP Apellis Pharmaceuticals, Inc. Transaction History

Wellington Management Group LLP

$529 Billion
Q2 2025

A detailed history of Wellington Management Group LLP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 8,976,962 shares of APLS stock, worth $207 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

8,976,962

Previous 12,303,252 27.04%

Holding current value

$207 Million

Previous $269 Million 42.25%

% of portfolio

0.03%

Previous 0.05%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$16.36 - $23.0 $54.4 Million - $76.5 Million	-3,326,290 Reduced 27.04%	8,976,962 $155 Million
Q1 2025 May 13, 2025	BUY	$21.87 - $34.63 $269 Million - $426 Million	12,303,252 New	12,303,252 $269 Million
Q4 2024 Feb 12, 2025	SELL	$26.18 - $35.42 $98.6 Million - $133 Million	-3,766,120 Reduced 24.19%	11,800,849 $377 Million
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $23.7 Million - $33.8 Million	-821,728 Reduced 5.01%	15,566,969 $449 Million
Q2 2024 Aug 13, 2024	BUY	$38.07 - $59.71 $50.7 Million - $79.5 Million	1,330,626 Added 8.84%	16,388,697 $629 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $834 Million - $1.09 Billion	15,058,071 New	15,058,071 $885 Million
Q4 2023 Feb 12, 2024	BUY	$37.14 - $64.82 $611 Million - $1.07 Billion	16,445,290 New	16,445,290 $984 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $201 Million - $759 Million	8,502,769 Added 127.59%	15,167,044 $577 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $124 Million - $151 Million	-1,614,164 Reduced 19.5%	6,664,275 $607 Million
Q1 2023 May 12, 2023	SELL	$46.59 - $66.96 $22.3 Million - $32.1 Million	-479,222 Reduced 5.47%	8,278,439 $546 Million
Q4 2022 Feb 13, 2023	SELL	$43.24 - $61.04 $51.9 Million - $73.2 Million	-1,199,755 Reduced 12.05%	8,757,661 $453 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $71 Million - $110 Million	-1,585,327 Reduced 13.73%	9,957,416 $680 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $93.2 Million - $157 Million	-2,656,551 Reduced 18.71%	11,542,743 $522 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $66.3 Million - $101 Million	1,868,641 Added 15.15%	14,199,294 $721 Million
Q4 2021 Feb 11, 2022	BUY	$30.74 - $49.16 $35.6 Million - $57 Million	1,159,081 Added 10.38%	12,330,653 $583 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $14.4 Million - $32 Million	457,747 Added 4.27%	11,171,572 $368 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $9.23 Million - $14.6 Million	225,721 Added 2.15%	10,713,825 $677 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $816,285 - $1.15 Million	-20,007 Reduced 0.19%	10,488,104 $450 Million
Q4 2020 Feb 12, 2021	BUY	$30.79 - $57.2 $1.7 Million - $3.16 Million	55,303 Added 0.53%	10,508,111 $601 Million
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $214,809 - $279,194	8,297 Added 0.08%	10,452,808 $315 Million
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $1.8 Million - $2.79 Million	72,513 Added 0.7%	10,444,511 $341 Million
Q1 2020 May 14, 2020	BUY	$17.91 - $44.33 $108 Million - $268 Million	6,054,734 Added 140.24%	10,371,998 $278 Million
Q4 2019 Feb 11, 2020	BUY	$22.1 - $30.8 $95.4 Million - $133 Million	4,317,264 New	4,317,264 $132 Million

Others Institutions Holding APLS

# of Institutions

295

Shares Held

132M

Call Options Held

2.97M

Put Options Held

623K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.54B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.

Account

Wellington Management Group LLP Apellis Pharmaceuticals, Inc. Transaction History